Skip to main content

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

Publication ,  Journal Article
Willett, CG; Boucher, Y; Duda, DG; di Tomaso, E; Munn, LL; Tong, RT; Kozin, SV; Petit, L; Jain, RK; Chung, DC; Sahani, DV; Kalva, SP; Zhu, AX ...
Published in: J Clin Oncol
November 1, 2005

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

November 1, 2005

Volume

23

Issue

31

Start / End Page

8136 / 8139

Location

United States

Related Subject Headings

  • Survival Rate
  • Rectal Neoplasms
  • Radiotherapy Dosage
  • Prognosis
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., … Lauwers, G. Y. (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol, 23(31), 8136–8139. https://doi.org/10.1200/JCO.2005.02.5635
Willett, Christopher G., Yves Boucher, Dan G. Duda, Emmanuelle di Tomaso, Lance L. Munn, Ricky T. Tong, Sergey V. Kozin, et al. “Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.J Clin Oncol 23, no. 31 (November 1, 2005): 8136–39. https://doi.org/10.1200/JCO.2005.02.5635.
Willett, Christopher G., et al. “Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.J Clin Oncol, vol. 23, no. 31, Nov. 2005, pp. 8136–39. Pubmed, doi:10.1200/JCO.2005.02.5635.
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 1;23(31):8136–8139.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

November 1, 2005

Volume

23

Issue

31

Start / End Page

8136 / 8139

Location

United States

Related Subject Headings

  • Survival Rate
  • Rectal Neoplasms
  • Radiotherapy Dosage
  • Prognosis
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Humans